Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | FGFRi treatment-emergent AEs in urothelial cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the management of treatment-emergent adverse events (AEs) in patients with locally advanced or metastatic urothelial cancer treated in the second-line with the fibroblast growth factor receptor inhibitor (FGFRi), erdafitinib. Recommended management is to hold erdafitinib at grade 2 toxicities before reaching higher grades to avoid a longer duration of paused treatment. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.